Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced financial results for the fourth quarter and full year of 2018. Total revenues for the full year of 2018 were $4,131.2 million, a 16% compared to 2017.
On a GAAP basis, diluted earnings per share (EPS) for the full year of 2018 was $0.35, an 82% decrease versus the prior year, inclusive of $1,183.0 million of expense related to the value of the in-process research and development assets acquired in 2018. Non-GAAP diluted EPS for the full year of 2018 was $7.92, a 35% increase versus the prior year.
Total revenues in the fourth quarter were $1,128.8 million, a 24% increase compared to the same period in 2017.
On a GAAP basis, diluted EPS in the quarter was $(0.20), a 254% decrease versus the prior year, inclusive of $379.3 million of expense related to the value of the in-process research and development asset acquired in connection with our acquisition of Syntimmune. Non-GAAP diluted EPS for the fourth quarter of 2018 was $2.14, a 45% increase versus the fourth quarter of 2017.
Said CEO Ludwig Hantson, "2018 was a transformational year for Alexion. I am proud of our many accomplishments, including entering rare neurology and making SOLIRIS for gMG Alexion's best launch ever, completing the Phase 3 program and launching ULTOMIRIS for PNH in the U.S., delivering groundbreaking Phase 3 data and submitting regulatory filings for SOLIRIS in NMOSD and rebuilding our pipeline through disciplined business development, all while continuing to grow our base business."
Shares hiked $1.86, or 1.3%, to $127.96
